Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. - Wikidata - awgldk - TriplyDB

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

http://www.wikidata.org/entity/Q46473402

about

Anti-vascular endothelial growth factor for diabetic macular oedema Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration Ranibizumab and bevacizumab for neovascular age-related macular degeneration Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin)Therapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathy Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials Geographic Atrophy and Choroidal Neovascularization in the Same Eye: A Review Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial Selective inhibition of retinal angiogenesis by targeting PI3 kinase Short-Term Topical Bevacizumab in the Treatment of Stable Corneal Neovascularization Is monthly retreatment with intravitreal bevacizumab (Avastin) necessary in neovascular age-related macular degeneration?Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients.Managing bevacizumab-induced intraocular inflammation.Long-term success of intravitreal bevacizumab for choroidal neovascularization associated with choroidal osteoma.Evolving European guidance on the medical management of neovascular age related macular degeneration.Macular degeneration: recent advances and therapeutic opportunities.Effect of systemic bevacizumab therapy on retinal pigment epithelial detachment.Age-related macular degeneration--emerging pathogenetic and therapeutic concepts.A review of drug options in age-related macular degeneration therapy and potential new agents.Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.Autologous translocation of the choroid and RPE in age-related macular degeneration: 1-year follow-up in 30 patients and recommendations for patient selection.Guidance for the treatment of neovascular age-related macular degeneration.Clinical applications and new developments of optical coherence tomography: an evidence-based review.Ocular photodynamic therapy--standard applications and new indications. Part 2. Review of the literature and personal experience.Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits.Toxicity and intraocular properties of a novel long-acting anti-proliferative and anti-angiogenic compound IMS2186.A reproducible and quantifiable model of choroidal neovascularization induced by VEGF A165 after subretinal adenoviral gene transfer in the rabbit.Surgical management of retinopathy of prematurity.Intravitreal bevacizumab for treatment of diabetic macular edema Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib.Age-related macular degeneration: current treatments.Current and emerging therapies for the treatment of age-related macular degeneration Inhibition of choroidal neovascularization by topical application of angiogenesis inhibitor vasostatin.Pegaptanib Sodium versus Pegaptanib Sodium Combined with Macular Laser Photocoagulation or Laser Alone for Diabetic Macular Edema The PEG-PCL-PEG Hydrogel as an Implanted Ophthalmic Delivery System after Glaucoma Filtration Surgery; a Pilot Study.Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?

P2860

Q24193083-CD1E04BA-98A7-45A1-B256-F24155A6ACBB Q24202071-73593A17-504A-4A5C-AE21-2F9638B49AF5 Q24240165-180CEC62-3130-4A5F-B370-BCEEB9379414 Q24242242-B8546D35-ACE9-4830-B27D-C7EC94AC46A3 Q24243234-67A2F2C1-6168-47D2-9BC2-C74B369612DF Q24616209-0BEB3F3A-4539-4365-BCB3-C92CA5A3538E Q24674358-8AFF3842-6E44-46C6-8102-643224888049 Q26823757-F0726D91-78D7-4391-8782-8C5F0CCE683A Q27021701-3D9DCF5F-8442-4947-9137-4F9F47E7548E Q28049700-5824EFBF-4953-4CF1-B3B8-5213203F267B Q28074640-DD27E6C8-5CFA-4EC4-AC89-1D583FDFF8D2 Q28294611-6F202C6B-264B-4213-9FEE-FE777B894936 Q28471888-6E7F014A-4CF9-4F8B-8A93-08F88AF5042C Q29999764-77C9A3AD-98A2-45D0-81BF-8469956490BF Q30436143-852BDDD8-6D2A-42CA-9998-F30940CEC5E1 Q30451413-8414AE70-FAFE-4B8C-908E-B9E79421E357 Q30463399-FFE19B48-81A8-43B5-96AC-29605308C778 Q30474521-1A7257F0-6943-4E81-B594-B4E4CA0AFCF3 Q33255038-1E016A71-5E8B-422E-AE09-AB89354F5CFF Q33260025-9F83E460-445F-4A31-B6C3-CC3623D61A89 Q33260828-9C82AE2B-D044-4E57-A2D0-75EEE689E594 Q33263472-BEF9EA04-9B82-4B15-867F-6238AF3E621D Q33263803-94EE8089-D2CA-4939-A5E7-EFCDEF6AF47E Q33287060-D3EE566A-43DF-44A2-A172-099FB75AF5F4 Q33291323-BF0958D1-B36C-48CB-BD4A-F50D1FC56F69 Q33291861-A99C0928-CCF7-4683-8288-F9F004283329 Q33294081-8CED5B4D-E845-4B18-95AC-DF18E7C7D298 Q33295490-C15EEDB5-6C17-4F29-A611-55AC356B688B Q33335166-E9E455F7-734D-40E9-8A26-3C22DF79CD88 Q33348983-88F35C33-6716-4A59-B85B-93320D4063FA Q33358094-A2E7BD0A-7870-489A-B4C7-2F116806F8E5 Q33366951-908BF833-8225-49EA-B97B-97F94A1686CA Q33425236-67DE4573-93C1-4F6C-A05F-857E627E04C7 Q33429798-6A26FF47-3434-4820-8483-1442F2E4BA5F Q33492348-00CD9325-BD69-4A4E-947F-DBE91565EB56 Q33492370-503A020E-D62D-4040-8CF0-13D50BF03946 Q33505319-851B3B58-29C1-4E53-8001-E0E4A14F5D4B Q33546338-F3DB1660-FC1A-4C66-A507-B0304AEAE780 Q33569881-BBC66A1A-6F65-401D-A4FB-F878E4D65321 Q33571004-77A559CB-9306-4338-B880-51AB50CF776B

P2860

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

http://www.wikidata.org/entity/Q46473402

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

@en

type

label

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

@en

prefLabel

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

@en

P1433

Q46473402-76D8F369-C23C-4B98-9CC3-5D236C5C6697

P1476

Q46473402-740DEFCA-757B-40A4-B1B9-68B1ECCCEDBA

P2093

Q46473402-657336E6-CB4C-401B-B071-2606C06BCBA5

Q46473402-93F70008-90BC-456B-B982-C852616F9F47

Q46473402-BAACC788-ABFC-4844-BDED-E7B79D386347

Q46473402-F099822A-6565-4E29-97B5-AC63C0440C9A

Q46473402-F373BE7A-6399-437D-9922-3F0A468CA98C

Q46473402-FDB8F1DD-6226-4258-A18F-B31BFDAF154A

P304

Q46473402-128A349A-5E1B-4B6D-B596-35FCF875CD59

P31

Q46473402-1E75EC46-A936-4B73-80EC-8B19AE7CB6F4

P356

Q46473402-54C89BC5-1A76-4608-92D9-589213649CC6

P433

Q46473402-0B841A05-3D4F-470D-A78D-F54ECA0405A6

P478

Q46473402-F30568EA-C6FD-4A20-B5DF-6D436CDF0141

P577

Q46473402-8E3913E2-8FE2-441D-B615-FECD5FB29923

P5875

Q46473402-A7C5C4DB-6216-4BDD-9C18-2F106638F51B

P698

Q46473402-2FAF8CA4-50E2-42D4-8CC6-75C75CAB883C

P921

Q46473402-6E833FB0-F414-41E7-AB7C-A3670F27A93B

P356

J.OPHTHA.2005.11.019

P1433

P1476

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

@en

P2093

Alessandro A Castellarin

http://www.w3.org/2001/XMLSchema#string

Dante J Pieramici

http://www.w3.org/2001/XMLSchema#string

Ma'an A Nasir

http://www.w3.org/2001/XMLSchema#string

Matthew J Giust

http://www.w3.org/2001/XMLSchema#string

Melvin D Rabena

http://www.w3.org/2001/XMLSchema#string

Robert L Avery

http://www.w3.org/2001/XMLSchema#string

P304

363-372.e5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.OPHTHA.2005.11.019

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P577

2006-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7315233

http://www.w3.org/2001/XMLSchema#string

P698

16458968

http://www.w3.org/2001/XMLSchema#string

P921